[1] EATON B R,SCHWARZ R,VATNER R,et al.Osteosarcoma[J].Pediatric Blood Cancer,2021,68(Suppl 2):e28352. [2] JIANG J,PAN H,LI M,et al.Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm[J].Sci Rep,2021,11(1):5542. [3] LILIENTHAL I,HEROLD N.Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma:A review of current and future strategies[J].Int J Mol Sci,2020,21(18):6885. [4] LI S,ZHANG H,LIU J,et al.Targeted therapy for osteosarcoma:a review[J].J Cancer Res Clin Oncol,2023,149(9):6785-67797. [5] SU Q,WANG J,WU Q,et al.Sanguinarine combats hypoxia-induced activation of EPHB4 and HIF-1α pathways in breast cancer[J].Phytomedicine,2021,84:153503. [6] NANAMIYA R,SAITO-KOYAMA R,MIKI Y,et al.EPHB4 as a novel target for the EGFR-independent suppressive effects of osimertinib on cell cycle progression in non-small cell lung cancer[J].Int J Mol Sci,2021,22(16):8522. [7] XU C,GU L,KUERBANJIANG M,et al.Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake[J].Oncogene,2023,42(2):99-112. [8] BHATIA S,NGUYEN D,DARRAGH L B,et al.EPHB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment[J].Nat Commun,2022,13(1):3535. [9] ZHU M,GONG Z,WU Q,et al.Homoharringtonine suppresses tumor proliferation and migration by regulating EPHB4-mediated β-CATENIN loss in hepatocellular carcinoma[J].Cell Death Dis,2020,11(8):632. [10] FULORIA S,YADAV G,MENON S V,et al.Targeting the WNT/β-CATENIN cascade in osteosarcoma:The potential of ncRNAs as biomarkers and therapeutics[J].Pathol Res Pract,2024,259:155346. [11] ARORA S,SCOTT A M,JANES P W.Eph receptors in cancer[J].Biomedicines,2023,11(2):315. [12] ULLAH A,RAZZAQ A,ZHOU C,et al.Biological significance of EPHB4 expression in cancer[J].Curr Protein Pept Sci,2024,25(3):244-255. [13] SCALIA P,MAURANCY J,GIORDANO A,et al.Transcriptional and post-translational control mechanisms for EPHB4 expression in physiology and cancer disease[J].Crit Rev Eukaryot Gene Expr,2021,31(2):83-88. [14] YAN D,CUI D,ZHU Y,et al.M6PR- and EPHB4-Rich exosomes secreted by serglycin-overexpressing esophageal cancer cells promote cancer progression[J].Int J Biol Sci,2023,19(2):625-640. [15] ZHANG Y,LIU Z,YANG X,et al.H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts[J].Theranostics,2021,11(3):1473-1492. [16] ZHU H,CHEN D,XIE X,et al.Melittin inhibits lung metastasis of human osteosarcoma:Evidence of WNT/β-CATENIN signaling pathway participation[J].Toxicon,2021,198:132-142. [17] LIN Y,ZHAN M,CHEN X,et al.Biological function of EPHB4 in the aging process of vascular endothelial cells:mtDNA molecular mechanism and MAPK/PGC-1/TFAM signaling pathway[J].Int J Biol Macromol,2024,293:138536. [18] SHAO L,YE Q,JIA M.miR-130-3p Promotes MTX-Induced immune killing of hepatocellular carcinoma cells by targeting EPHB4[J].J Healthc Eng,2021,2021:4650794. [19] AZEVEDO MARTINS J M,RABELO-SANTOS S H,DO AMARAL WESTIN M C,et al.Tumoral and stromal expression of MMP-2,MMP-9,MMP-14,TIMP-1,TIMP-2,and VEGF-A in cervical cancer patient survival:a competing risk analysis[J].BMC Cancer,2020,20(1):660. [20] BAI C,MA X,WANG X,et al.Correlation between pathological features and protein expressions of TfR1,VEGF and MMP-9 in patients with osteosarcoma[J].Am J Transl Res,2022,14(7):4562-4572. [21] DING L,LIU T,QU Y,et al.lncRNA MELTF-AS1 facilitates osteosarcoma metastasis by modulating MMP14 expression[J].Mol Ther Nucleic Acids,2021,26:787-797. |